Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. |
| |
Authors: | P Hadváry H Lengsfeld H Wolfer |
| |
Affiliation: | F. Hoffmann-La Roche & Co., Ltd., Pharmaceutical Research Department, Basel, Switzerland. |
| |
Abstract: | Tetrahydrolipstatin inhibits pancreatic lipase from several species, including man, with comparable potency. The lipase is progressively inactivated through the formation of a long-lived covalent intermediate, probably with a 1:1 stoichiometry. The lipase substrate triolein and also a boronic acid derivative, which is presumed to be a transition-state-form inhibitor, retard the rate of inactivation. Therefore, in all probability, tetrahydrolipstatin reacts with pancreatic lipase at, or near, the substrate binding or active site. Tetrahydrolipstatin is a selective inhibitor of lipase; other hydrolases tested were at least a thousand times less potently inhibited. |
| |
Keywords: | |
|
|